Replies to post #196091 on Biotech Values

[steveporsche]

"ABBV expects Japan to approve V-Pak during 4Q15."

I think ABBV already gained V-Pak approval in Japan near the end of 3Q15:

http://www.fiercepharmaasia.com/story/abbvie-wins-viekirax-nod-japan-expected-competition-seen-tight/2015-09-29

http://abbvie.mediaroom.com/2015-09-28-AbbVies-VIEKIRAX-ombitasvir-paritaprevir-ritonavir-tablets-Receives-Approval-in-Japan-for-the-Treatment-of-Genotype-1-Chronic-Hepatitis-C

[DewDiligence]

Survey results: ABBV’s V-Pak Sales Guidance Ending 2015

Background: ABBV has guided investors that Viekira Pak will have worldwide annualized sales of more than $3B ending 2015—i.e. as of 12/31/15. For comparison, V-Pak’s annualized run rate during 2Q15 was $1.54B in the US and EU alone (#msg-115760387). V-Pak was approved in Japan in late September and will be launched there during 4Q15.


There were 20 votes.


Q: When ABBV releases 3Q15 financial results, what is the most
likely action with respect to V-Pak sales guidance ending 2015?

• ABBV will increase guidance: 10%
• ABBV will decrease guidance: 30%
• ABBV will leave guidance unchanged: 60%


Thanks to all of the participants for participating.

p.s. ABBV reports 3Q15 results on 10/30/15.